- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01310049
LEO 32731 - A Study in Healthy Male Subjects
4 november 2013 bijgewerkt door: LEO Pharma
LEO 32731 - A Phase I, Single-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 32731 in healthy male subjects.
The trial will be performed in three parts.
In Part 1, single doses of LEO 32731 will be administered to healthy male subjects.
In Part 2, the effect of food on the single oral dose pharmacokinetic will be investigated.
In Part 3, multiple doses of LEO 32731 will be administered to healthy male subjects.
Studie Overzicht
Studietype
Ingrijpend
Inschrijving (Werkelijk)
111
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Leeds, Verenigd Koninkrijk
- Covance Clinical Research Unit Ltd.
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 55 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria:
- Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the study restrictions.
- Subjects will be Caucasian males between 18 and 55 years of age and with a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.
- Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is NOT acceptable).
Exclusion Criteria:
- Subjects who are not, or whose partners are not willing to use appropriate contraception (such as condom) with spermicidal foam/gel/film/cream/suppository from the time of the first dose until 3 months after the final dosing occasion. Male subjects whose partners are of child-bearing potential must also agree to use an additional highly effective method of contraception
- Subjects who have received any prescribed systemic or topical medication within 14 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
- Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
- Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
- Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity), or a marketed drug within the past 3 months prior to the first dosing occasion.
- Subjects who have donated any blood, plasma or platelets in 3 months prior to screening or who have made donations on more than two occasions within the 12 months preceding the first dose administration.
- Subjects with a significant history of drug allergy as determined by the Investigator.
- Subjects who have any clinically significant allergic disease (excluding non-active hayfever) as determined by the Investigator.
- Subjects who have a supine blood pressure and supine pulse rate at screening higher than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 50 bpm, respectively
- Subjects who consume more than 28 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits).
- Subjects with a positive urine drug screen or alcohol breath test result at screening or first admission.
- Subjects who smoke or who have smoked in the 3 months prior to first dose administration.
- Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator.
- Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator.
- Subjects who are known to have serum hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the test for HIV antibodies.
- Subjects who have confirmed active/latent tuberculosis (TB).
- Subjects who, in the opinion of their General Practitioner (GP) or the Investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol.
- Subjects who have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risk of participating in the study; such as QTcB interval >450 msec, 2nd or 3rd degree Atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolff-Parkinson-White Syndrome defined as PR<110 msec, confirmed by a repeat ECG.
- Subjects who have previously taken part in or withdrawn from this study.
- Subjects who, in the opinion of the Investigator, should not participate in the study.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: LP0058 oral solution (0.050 mg/mL)
LEO 32731
|
|
Experimenteel: LP0058 oral solution (0.200 mg/mL)
LEO 32731
|
|
Placebo-vergelijker: LP0058 oral solution (placebo)
Placebo
|
|
Experimenteel: LP0058 capsule 1-120 mg
LEO 32731
|
|
Placebo-vergelijker: LP0058 capsule (placebo)
Placebo
|
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Number of subjects with AEs and change from baseline in vital signs (blood pressure, pulse rate and oral body temperature), ECG, telemetry and clinical laboratory.
Tijdsspanne: 7 days after last dosing
|
7 days after last dosing
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
LEO 32731 and metabolites in blood and urine
Tijdsspanne: 72 hours after dosing
|
72 hours after dosing
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 maart 2011
Primaire voltooiing (Werkelijk)
1 augustus 2012
Studie voltooiing (Werkelijk)
1 november 2012
Studieregistratiedata
Eerst ingediend
2 maart 2011
Eerst ingediend dat voldeed aan de QC-criteria
4 maart 2011
Eerst geplaatst (Schatting)
7 maart 2011
Updates van studierecords
Laatste update geplaatst (Schatting)
5 november 2013
Laatste update ingediend die voldeed aan QC-criteria
4 november 2013
Laatst geverifieerd
1 maart 2011
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- LP0058-S01
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezonde onderwerpen
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op LEO 32731
-
LEO PharmaVoltooid
-
LEO PharmaVoltooid
-
LEO PharmaVoltooidPsoriasis vulgarisDuitsland
-
LEO PharmaVoltooid
-
LEO PharmaVoltooidActinische keratoseVerenigde Staten
-
LEO PharmaVoltooid
-
LEO PharmaVoltooidAtopische dermatitisNederland
-
LEO PharmaVoltooid
-
LEO PharmaVoltooidOmgekeerde PsoriasisDuitsland
-
LEO PharmaBeëindigdDiscoïde lupus erythematosusVerenigde Staten, Frankrijk, Duitsland, Denemarken